A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer

BACKGROUND: ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI) specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating mutations or EGFR T790M resistance mutations. The current study examines the efficacy, safety, and tolerability of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, R J, Shepherd, F A, Krivoshik, A, Jie, F, Horn, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736319/
https://www.ncbi.nlm.nih.gov/pubmed/31070709
http://dx.doi.org/10.1093/annonc/mdz128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736319/
https://www.ncbi.nlm.nih.gov/pubmed/31070709
http://dx.doi.org/10.1093/annonc/mdz128

Ejemplares similares